Showing 1-30 of 334 results for "07741"
Adam C Palmer et al.
Cell, 171(7), 1678-1691 (2017-12-16)
Combination cancer therapies aim to improve the probability and magnitude of therapeutic responses and reduce the likelihood of acquired resistance in an individual patient. However, drugs are tested in clinical trials on genetically diverse patient populations. We show here that...
Erhan Tenekecioglu et al.
International journal of cardiology, 227, 467-473 (2016-11-15)
Local hemodynamic changes are one of the main factors that determine the vessel wall biological response after stent/scaffold implantation. Computational fluid dynamic studies provide an opportunity to investigate the rheological effects of implanted stent/scaffold. The aim of this study was...
Andrea Petronio Rossi et al.
Journal of nephrology, 31(4), 613-620 (2018-03-20)
Renal transplant (RTX) recipients seem to experience a better quality of life compared to dialysis patients. However, the factors responsible for this positive effect are not completely defined. Conceivably, a change in the physical performance of these patients could play...
Dolly Aguilera et al.
Journal of pediatric hematology/oncology, 36(7), e448-e451 (2013-11-28)
Brain subependymal giant cell astrocytomas (SEGAs) in patients with tuberous sclerosis have been reported to respond to everolimus. A 15-year-old male patient with intractable seizures and multiple SEGAs of the brain developed leptomeningeal enhancement and multiple metastatic, histologically confirmed SEGAs...
Jeehoon Kang et al.
BMC cardiovascular disorders, 18(1), 130-130 (2018-06-30)
Nonculprit lesions are the major cause of future cardiovascular events. However, the natural course of nonculprit lesions and angiographic predictors of plaque progression are not well-studied. The purpose of our study was to observe the natural course of nonculprit lesions...
Miklós Tóth
Orvosi hetilap, 154(39), 1556-1564 (2013-09-24)
The author aims to review the established medical treatment options of neuroendocrine tumours, which have expanded greatly in recent years and present the most important aspects to be considered in planning patients' management. Medical treatment is usually considered in advanced...
Roberto Buzzoni et al.
OncoTargets and therapy, 10, 5013-5030 (2017-10-31)
Recently, everolimus was shown to improve median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) tract compared with placebo (HR, 0.48; 95% CI, 0.35-0.67; identifier: NCT01524783....
Dorien Van den Bossche et al.
Clinical biochemistry, 47(15), 112-115 (2014-07-09)
Liquid chromatography tandem mass spectrometry has become increasingly popular in clinical laboratories over the last decade due to the inherent sensitivity and specificity of the technology. Nevertheless, full automation and hence application in routine laboratories is still hampered by laborious...
Shirish M Gadgeel et al.
Cancer chemotherapy and pharmacology, 72(5), 1089-1096 (2013-09-24)
Everolimus, an oral inhibitor of mammalian target of rapamycin, can augment the efficacy of HER inhibitors in preclinical studies. This study was conducted to determine the safety and pharmacokinetics (PK) of the combination of lapatinib, a Her1 and 2 inhibitor...
Sahar Salehi et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 18(5), 1096-1109 (2017-10-19)
Antibody-mediated rejection (AMR) resulting in transplant allograft vasculopathy (TAV) is the major obstacle for long-term survival of solid organ transplants. AMR is caused by donor-specific antibodies to HLA, which contribute to TAV by initiating outside-in signaling transduction pathways that elicit...
Marine Gilabert et al.
Bulletin du cancer, 101(3), 325-333 (2014-04-03)
Phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is commonly deregulated in breast cancer and has been involved in resistance to endocrine therapy. In the BOLERO-2 study, the addition of everolimus, a selective inhibitor of mTOR protein, to exemestane was associated...
Jiryeon Jang et al.
Translational oncology, 10(3), 304-310 (2017-03-23)
Although targeting angiogenesis with tyrosine kinase inhibitors (TKIs) has become standard of care in the treatment of clear cell renal cell carcinoma (RCC), resistance mechanism are not fully understood, and there is a need to develop new therapeutic options overcoming...
Parvin F Peddi et al.
Cancer treatment reviews, 40(2), 320-326 (2013-09-10)
The mammalian target of rapamycin (mTOR) inhibitor class of drugs represents the newest addition to the armamentarium of therapies for hormonally driven breast cancer. It has recently been shown that the addition of mTOR inhibitor everolimus to aromatase inhibitors in...
A W Tolcher et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 26(1), 58-64 (2014-10-26)
This phase Ib trial investigated the safety, tolerability, and recommended phase II dose and schedule of the MEK inhibitor trametinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus. Secondary objectives included pharmacokinetic (PK) characterization and evaluation of...
Tsung-Ying He et al.
Annals of surgical oncology, 21 Suppl 4, S703-S710 (2014-06-01)
Liver kinase B1 (LKB1) loss by gene mutation, loss of heterozygosity, and promoter methylation rarely occurs in colorectal cancer. We wondered whether LKB1 loss could be deregulated at the transcriptional level to promote tumor progression and poor outcome in colorectal...
Ana M Molina et al.
Cancer chemotherapy and pharmacology, 73(1), 181-189 (2013-11-06)
Lenvatinib is an oral multi-targeted tyrosine kinase inhibitor of VEGFR1-3, FGFR1-4, PDGFRβ, RET, and KIT. Everolimus is an oral mammalian target of rapamycin inhibitor approved for advanced renal cell carcinoma (RCC). This phase 1b study assessed safety, maximum tolerated dose...
Eric E Gardner et al.
Cancer research, 74(10), 2846-2856 (2014-03-13)
Overexpression of the antiapoptotic protein Bcl-2 is observed in the majority of small cell lung cancer (SCLC) cases and is associated with resistance to chemotherapy. While targeting Bcl-2 in hematologic malignancies continues to show signs of promise, translating the BH3...
Roberto Iacovelli et al.
American journal of clinical oncology, 37(6), 611-615 (2013-02-08)
Prognosis of metastatic renal cell carcinoma (mRCC) has markedly improved in the recent years. Several factors such as precocious diagnosis, better supportive care, and an increased number of targeted therapies are responsible for this progress. From 2006 to date, 7...
Georgia Karayannopoulou et al.
Anticancer research, 33(9), 3711-3714 (2013-09-12)
Mammalian Target of Rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, have been shown to reduce cutaneous carcinogenesis in organ-transplant recipients requiring for immunosuppressive treatment to prevent from allograft rejection. Clinical observations suggest that cutaneous squamous cell carcinomas (SCC) are...
Elke Tatjana Aristizabal Prada et al.
Endocrine-related cancer, 25(5), 547-560 (2018-03-23)
Tropomyosin receptor kinase (Trk) inhibitors are investigated as a novel targeted therapy in various cancers. We investigated the in vitro effects of the pan-Trk inhibitor GNF-5837 in human neuroendocrine tumor (NET) cells. The human neuroendocrine pancreatic BON1, bronchopulmonary NCI-H727 and...
Norihiro Kobayashi et al.
Heart and vessels, 31(12), 1930-1942 (2016-03-05)
The efficacy of second-generation drug-eluting stent (DES) for the treatment of left main disease (LM) and/or three vessel disease (3VD) remains unclear. We compared 2-year outcomes of second- versus first -generation DES implantation among patients with LM and/or 3VD and...
Lisette Okkels Jensen et al.
JACC. Cardiovascular interventions, 7(8), 840-848 (2014-08-05)
The study sought to compare the risk of late outcome with a focus on very late definite stent thrombosis of the everolimus-eluting stent (EES) with that of the sirolimus-eluting stent (SES) at 3-year follow-up. In the SORT OUT IV (SORT...
Johanna C Bendell et al.
Investigational new drugs, 33(1), 187-193 (2014-10-23)
To determine the maximum tolerated dose (MTD) of the combination of linsitinib (OSI-906), a dual inhibitor of IGFR and IR tyrosine kinase activity, and everolimus as treatment for patients with refractory metastatic colorectal cancer (mCRC). Eligible adult patients with refractory...
Mario Campone et al.
European journal of cancer (Oxford, England : 1990), 49(12), 2621-2632 (2013-06-06)
Everolimus (EVE; an inhibitor of mammalian target of rapamycin [mTOR]) enhances treatment options for postmenopausal women with hormone-receptor-positive (HR(+)), human epidermal growth factor receptor-2-negative (HER2(-)) advanced breast cancer (ABC) who progress on a non-steroidal aromatase inhibitor (NSAI). This is especially...
Hui Jun Lim et al.
Journal of cancer research and clinical oncology, 141(4), 671-689 (2014-08-26)
PTEN is an essential tumour suppressor gene which encodes a phosphatase protein that antagonises the PI3K/Akt/mTOR antiapoptotic pathway. Impairment of this tumour suppressor pathway potentially becomes a causal factor for development of malignancies. This review aims to assess current understanding...
Ian T Meredith et al.
The American journal of cardiology, 113(7), 1117-1123 (2014-02-18)
In the randomized PLATINUM trial, the PROMUS Element platinum-chromium everolimus-eluting stent (PtCr-EES; Boston Scientific, Natick, Massachusetts) was noninferior to the XIENCE V cobalt-chromium everolimus-eluting stent (CoCr-EES; Boston Scientific and Abbott Vascular, Santa Clara, California) for the primary end point of...
Love Sharma et al.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 121, 283-296 (2018-09-13)
Non-alcoholic fatty liver disease (NAFLD) is often linked with impaired hepatic autophagy. Here, we studied the alterations in hepatocellular autophagy by high cholesterol and high-fat diet (HC-HF) diet in C57BL/6J mice, and by palmitic acid (PA), in AML-12 and HepG2...
Atsushi Ohtsu et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(31), 3935-3943 (2013-09-18)
The oral mammalian target of rapamycin inhibitor everolimus demonstrated promising efficacy in a phase II study of pretreated advanced gastric cancer. This international, double-blind, phase III study compared everolimus efficacy and safety with that of best supportive care (BSC) in...
Tao Peng et al.
Journal of cellular biochemistry, 118(9), 2722-2730 (2017-02-07)
Pancreatic cancer is the fourth leading cause of cancer-related death in the United States. While Gemcitabine-based chemotherapy is the first-line treatment for locally advanced pancreatic cancer, its resistance is a large obstacle in the field. Understanding the molecular basis of...
I Ray-Coquard et al.
British journal of cancer, 108(9), 1771-1777 (2013-04-25)
Patients with recurrent/metastatic endometrial cancer that progresses after chemotherapy have limited treatment options and poor outcomes. Preclinical data suggest the oral mammalian target of rapamycin inhibitor everolimus may provide clinical benefit in these patients. In this multicenter, open-label, phase 2...

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.